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FIGURE 1. Positioning and separation of cannulas in the percutaneous cannulation technique for
extracorporeal membrane oxygenation. A indicates the intra-aortic balloon pump; B indicates
the percutaneous femoral vein; C indicates the reperfusion catheter in the superficial femoral artery
(10 cm below the inguinal ligament); and D indicates the percutaneous femoral artery.
Letters to the Editorprocedure is a way of avoiding any
hazardous puncture, particularly in
the case of patients with low flow
and low pulsatility or cardiac arrest.
Moreover, this practice also allows
the visualization of the vascular inser-
tion of the cannula, a situation that is
reassuring in cases of coagulation
impairments.
Therefore, even if venoarterial
ECMO is usually provided as a surgi-
cal technique, it seems logical that this
procedure takes place in the intensive
care unit in emergency cases. In this
regard, our team recommends 2
kinds of procedures: (1) a Seldinger
technique after surgical incision or
(2) a percutaneous ultrasound-guided
insertion technique derived from the
intensive care unit vascular catheter
insertion. This latter technique guides
the femoral vessel puncture, signifi-
cantly reduces such complications as
bleeding and hematoma, and allows
the correct insertion of wires,3 even
if there is no pulse. Furthermore, in
this percutaneous technique, as
described by Lamb and associates,4
the 2 cannulas should be separated, a
cannula positioned on the right vessel
and the other on the opposite side
(Figure 1).
In summary, we do recommend
either a surgical approach associated
with vascular puncture by the Sel-
dinger technique or a strict1996 The Journal of Thoracic andpercutaneous ultrasonographically
guided approach, including the intro-
duction of the reperfusion cannula.
We believe that the crucial points to
avoid leg ischemia are as follows: (1)
the femoral arterial cannula should
be as thin as possible (maximum size
17F in women and maximum size
19F in men) and (2) the reperfusion
cannula should be introduced system-
atically during the 6 hours after
ECMO implantation.
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j.jtcvs.2014.02.031Reply to the Editor:
I read with interest the letter of
Banfi and colleagues referring to
our brief communication on surgical
technique1 and appreciate their
comments. I agree with both of their
suggestions regarding cannulation
for extracorporeal membrane
oxygenation, surgical cutdown and
wire-guided cannulation or a fully
percutaneous approach exchanging
already inserted catheters over the
wire. This is indeed our standard pri-
mary approach when time, place
(catheterization laboratory), and the
clinical situation of the patient
permit it. In ‘‘crash and burn’’ sce-
narios, the approach might change.2
The surgical technique that we
described in our communication is
a safe way to convert a percutaneous
cannulation to a transprosthetic one
when a distal perfusion cannula
cannot be safely inserted. Further,
in patients needing higher flow rates
than a percutaneous cannula can
provide safely, the transprosthetic
Letters to the Editorapproach allows the use of the whole
lumen of the artery for perfusion,
thus avoiding high pressure gradients
across the cannula. The risk of infec-
tion of the vascular prosthesis in
cases of longer extracorporeal mem-
brane oxygenation perfusion has to
be weighted against potential diam-
eter limitations of the perfusion
cannula and complications of the
distal perfusion cannula technique
(kinking, dislocation, thrombosis).
I thank Banfi and colleagues for
their interest in our work and their
mindful comments.
Stefanos Demertzis, MD
Department of Cardiac Surgery
Cardiocentro Ticino
Lugano, Switzerland
University of Bern
Bern, Switzerland
References
1. Demertzis S, Carrel T. Transformation of percuta-
neous venoarterial extracorporeal membrane
oxygenation access to a safe peripheral arterial can-
nulation. J Thorac Cardiovasc Surg. 2013;146:
1293-4.
2. Demertzis S, Carrel T. Rapid peripheral arterial
cannulation for extracorporeal life support with un-
impaired distal perfusion. J Thorac Cardiovasc
Surg. 2011;141:1080-1.
http://dx.doi.org/10.1016/
j.jtcvs.2014.02.067REPLY TO ‘‘IS THE CAUSE OF
DEATH IN HYPERTROPHIC
CARDIOMYOPATHY LOW
PRESSURE GRADIENT IN LEFT
VENTRICULAR OUTFLOW?’’
Reply to the Editor:
Kestelli and associates1 may have
misunderstood the analysis in my
group’s article, ‘‘Expanding the
Indications for Septal Myectomy in
Patients With Hypertrophic Cardio-
myopathy: Results of Operation in
Patients With Latent Obstruction.’’2
As shown in Table 2 in our original
article,2 preoperative medication use
was generally similar between the pa-
tientswith latent obstruction (gradients
of 30 mm Hg or less) and those with
high resting gradients (greater thanThe Journal30 mm Hg). We did not analyze sur-
vival according to preoperative drug
use, and if, in fact, medications
had any substantial impact on late sur-
vival, such an effect would likely be
related to postoperative medication
use rather than to preoperative medica-
tion use.
We did not postulate that wall thick-
ness had any impact on survival one
way or the other. In our previous
studies, however, left ventricular
mass and wall thickness were not
found to be predictors of late survival
after myectomy for hypertrophic
obstructive cardiomyopathy, a finding
that is in contrast to the results of nat-
ural history studies of patients who
were not treated surgically.3
The apparent minor difference in
survival of patients with latent
obstruction in our original Figures 2
and 4 is actually due to a slight differ-
ence in the number of patients for
whom matching was possible in the
age-matched and sex-matched
population.
The conclusion drawn by Kestelli
and associates1 from the article by
Ommen and colleagues4 is incorrect.
In that series, which also came from
our clinic, the late survival of patients
with obstructive hypertrophic cardio-
myopathy who underwent myectomy
was similar to the survival of patients
who had hypertrophic cardiomyopa-
thy without obstruction. Left ventricu-
lar outflow tract obstruction left
untreated in patients with hypertro-
phic cardiomyopathy is associated
with reduced late survival,5 and this
situation seems to be improved after
myectomy.
Hartzell Schaff, MD
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LOBECTOMY BE REPLACED
BY SUBLOBAR RESECTION
IN PATIENTS WITH STAGE I
NON–SMALL CELL LUNG
CANCER?
To the Editor:
We read with interest the article by
Altorki and colleagues1 comparing
survival between patients treated
by sublobar (SLR) and lobar (LR)
resection for clinical stage IA
non–small cell lung cancer. SLR
is commonly considered only for
patients who cannot undergo
lobectomy. This practice is based on
a randomized trial published by the
Lung Cancer Study Group in 1995,2
which showed LR to be associated
with lower rates of local recurrence
and cancer-related death. In contrast,
Altorki and colleagues1 found
equivalent survival between SLR
and LR in clinical stage IA. We
congratulate them for this study
and believe that in the future their
conclusions could radically change
and enlarge the role of SLR in the
treatment of patients with non–small
cell lung cancer.y c Volume 147, Number 6 1997
